Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vasomotor Symptoms Clear all
Completed Phase 1Phase 2 Interventional Results available

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

NCT02865538
View directory record Official record
Conditions
Post-menopausal Vasomotor Symptoms
Interventions
BAY3427080, Placebo (for BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
DeLand, Florida • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer

NCT02338102
View directory record Official record
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

NCT00421031
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
DVS-233 SR
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
41
States / cities
Montgomery, Alabama • Peoria, Arizona • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2007 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

NCT01178892
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Placebo, Omega-3, Yoga, Exercise, Usual Activity
Dietary Supplement · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

NCT00875420
View directory record Official record
Conditions
Hot Flashes
Interventions
RAD1901, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

NCT00894543
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

NCT01942668
View directory record Official record
Conditions
Menopause
Interventions
Estradiol, Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause

NCT06385795
View directory record Official record
Conditions
Menopause Syndrome, Menopause, Hot Flashes
Interventions
NOE-115
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 21, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)

NCT02049164
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
AR08, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
41 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
San Diego, California • Colorado Springs, Colorado • Lakeworth, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

NCT00160342
View directory record Official record
Conditions
Hot Flushes, Menopause, Postmenopause
Interventions
Esterified Estrogens (EE) and Methyltestosterone (MT)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
1,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
88
States / cities
Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

NCT01361308
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Brisdelle (paroxetine mesylate), Placebo capsules
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
40 Years and older · Female only
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
74
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Yoga on Objective and Subjective Menopausal Hot Flashes

NCT01073397
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Yoga
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
45 Years to 58 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

NCT00031720
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Hot Flushes
Interventions
soy protein, isoflavones, Tamoxifen, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
14
States / cities
Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jul 21, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

NCT02653417
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
RAD1901, Placebo
Drug · Other
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

NCT03285672
View directory record Official record
Conditions
Hot Flashes
Interventions
FP-101, Placebo Comparator
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
40 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

NCT05312567
View directory record Official record
Conditions
Vasomotor Symptoms, Menopause
Interventions
FP-101
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
46 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Lomita, California • Long Beach, California • West Covina, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Jul 21, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313
View directory record Official record
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Fezolinetant, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

NCT05813067
View directory record Official record
Conditions
Vasomotor Symptoms, Postmenopausal Disorders
Interventions
JDS-HF 3.0, Placebo
Dietary Supplement
Lead sponsor
Bonafide Health
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lake Worth, Florida • Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 21, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

NCT00160173
View directory record Official record
Conditions
Postmenopausal Symptoms
Interventions
Estrogel, Placebo
Drug · Other
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jul 21, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 21, 2026, 10:23 PM EDT